P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies

2017 ◽  
Vol 128 (10) ◽  
pp. e326
Author(s):  
T. Ziemssen ◽  
D.L. Arnold ◽  
A. Bar-Or ◽  
G. Comi ◽  
H.P. Hartung ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Interferon Beta ◽  
Phase Iii ◽  
Resonance Imaging ◽  
Double Blind ◽  
Imaging Markers ◽  
Relapsing Multiple Sclerosis

Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect

2015 ◽  
Vol 21 (13) ◽  
pp. 1723-1729 ◽  
Author(s):  
A Voldsgaard ◽  
P Bager ◽  
E Garde ◽  
P Åkeson ◽  
AM Leffers ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Beneficial Effect ◽  
Gastrointestinal Symptoms ◽  
Early Period ◽  
Resonance Imaging ◽  
Trichuris Suis ◽  
Multiple Sclerosis Patients ◽  
Relapsing Multiple Sclerosis

Background: An observational study has suggested that relapsing–remitting multiple sclerosis patients with helminth infections have lower disease activity and progression than uninfected multiple sclerosis patients. Objective: To evaluate the safety and efficacy on MRI activity of treatment with TSO in relapsing MS. Methods: The study was an open-label, magnetic resonance imaging assessor-blinded, baseline-to-treatment study including ten patients with relapsing forms of multiple sclerosis. Median (range) age was 41 (24–55) years, disease duration 9 (4–34) years, Expanded Disability Status Scale score 2.5 (1–5.0), and number of relapses within the last two years 3 (2–5). Four patients received no disease modifying therapy, while six patients received IFN-β. After an observational period of 8 weeks, patients received 2500 ova from the helminth Trichuris suis orally every second week for 12 weeks. Patients were followed with serial magnetic resonance imaging, neurological examinations, laboratory safety tests and expression of immunological biomarker genes. Results: Treatment with Trichuris suis orally was well-tolerated apart from some gastrointestinal symptoms. Magnetic resonance imaging revealed 6 new or enlarged T2 lesions in the run-in period, 7 lesions in the early period and 21 lesions in the late treatment period. Two patients suffered a relapse before treatment and two during treatment. Eight patients developed eosinophilia. The expression of cytokines and transcription factors did not change. Conclusions: In a small group of relapsing multiple sclerosis patients, Trichuris suis oral therapy was well tolerated but without beneficial effect.

Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis

2005 ◽  
Vol 11 (6) ◽  
pp. 658-668 ◽  
Author(s):  
S Gupta ◽  
J M Solomon ◽  
T A Tasciyan ◽  
M M Cao ◽  
R D Stone ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Natural History ◽  
Interferon Beta ◽  
Resonance Imaging ◽  
Post Contrast ◽  
Contrast Magnetic Resonance Imaging ◽  
Contrast Magnetic Resonance ◽  
Degree Of Severity

Interferon-beta (IFNβ) reduces the number and load of new contrast-enhancing lesions (CELs) in patients with multiple sclerosis (MS). However, the ability of IFNβ to reduce lesion sizes and re-enhancements of pre-existing CELs has not been examined extensively. Activity of contrast re-enhancing lesions (Re-CELs) and contrast single-enhancing lesions (S-CELs) were monitored in ten patients with relapsingremitting (RR) MS. These patients underwent monthly post-contrast magnetic resonance imaging (MRIs) for an 18-month natural history phase and an 18-month therapy phase with subcutaneous IFNβ-1b, totaling 37 images per patient. The activity was analysed using the first image as a baseline and registering subsequent active monthly images to the baseline. There was a 76.4% reduction in the number of CELs with IFNβ therapy. The decrease was greater (P=0.003) for S-CELs (82.3%) than for Re-CELs (57.4%). S-CELs showed no changes in durations of enhancement and maximal lesion sizes with treatment. Exclusively for Re-CELs, IFNβ-1b significantly decreased maximal lesion sizes, total number of enhancement periods and total months of enhancement. Thus, IFNβ appears to be effective in reducing the degree of severity of inflammation among Re-CELs, as reflected by their reduced maximal lesion sizes and durations of enhancement.

scholarly journals Susac syndrome misdiagnosed as multiple sclerosis with exacerbation by interferon beta therapy

2017 ◽  
Vol 31 (2) ◽  
pp. 207-212 ◽  
Author(s):  
Hussein Algahtani ◽  
Bader Shirah ◽  
Muhammad Amin ◽  
Eyad Altarazi ◽  
Hashem Almarzouki
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Hearing Loss ◽  
Magnetic Resonance ◽  
Interferon Beta ◽  
Young Patients ◽  
Oligoclonal Bands ◽  
Resonance Imaging ◽  
Susac Syndrome ◽  
Retinal Artery

Susac syndrome is a rare autoimmune disorder characterised by the clinical triad of encephalopathy, retinopathy (branch retinal artery occlusions) and hearing loss. The diagnosis of Susac syndrome may be difficult initially, and it is not uncommon for patients with Susac syndrome to be misdiagnosed with multiple sclerosis. In this case report, we describe a patient who was diagnosed as having multiple sclerosis for three years, with further deterioration after starting treatment with interferon beta-1a. The patient had the triad of encephalopathy, branch retinal artery occlusions and sensorineural hearing loss. She had the classic magnetic resonance imaging appearance, with normal magnetic resonance imaging of the spinal cord and absence of oligoclonal bands in the cerebrospinal fluid. Our patient responded well to treatment with a combination therapy and discontinuation of interferon beta-1a. Our observations raise awareness about the importance of the early and correct diagnosis of Susac syndrome, which usually affects young patients, with an excellent prognosis if treated aggressively at an early stage of the disease. Susac syndrome is underdiagnosed and is not uncommonly misdiagnosed as multiple sclerosis. Susac syndrome is a great mimicker of multiple sclerosis, and establishing diagnostic criteria for this syndrome is very useful. In any patient presenting with a progressive disabling neurological disorder associated with callosal lesions and/or hearing loss, and/or visual loss especially in women, Susac syndrome should be suspected.

Sign in / Sign up

Export Citation Format

Share Document